vs
Side-by-side financial comparison of AC Immune SA (ACIU) and Moolec Science SA (MLEC). Click either name above to swap in a different company.
Moolec Science SA is the larger business by last-quarter revenue ($2.6M vs $1.4M, roughly 1.8× AC Immune SA). Moolec Science SA runs the higher net margin — -91.8% vs -1622.4%, a 1530.6% gap on every dollar of revenue.
AC Immune SA is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics and diagnostic solutions for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and rare tauopathies. It operates globally, partners with leading pharmaceutical enterprises, and prioritizes addressing unmet medical needs in neurological care segments.
Moolec Science SA is a global agricultural biotechnology and food technology company specializing in molecular farming. It uses engineered crop platforms to produce sustainable, cost-competitive animal-derived proteins for use in alternative meat, dairy products and food ingredients, serving food manufacturers, agribusinesses and consumer goods brands across North America, Europe and Latin America.
ACIU vs MLEC — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4M | $2.6M |
| Net Profit | $-23.3M | $-2.4M |
| Gross Margin | — | -25.5% |
| Operating Margin | -1484.5% | -77.9% |
| Net Margin | -1622.4% | -91.8% |
| Revenue YoY | 90.1% | — |
| Net Profit YoY | 6.9% | — |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $1.4M | — | ||
| Q4 24 | — | $2.6M | ||
| Q2 24 | $755.7K | — | ||
| Q3 23 | — | $1.7M | ||
| Q3 22 | $4.3M | — |
| Q2 25 | $-23.3M | — | ||
| Q4 24 | — | $-2.4M | ||
| Q2 24 | $-25.0M | — | ||
| Q3 23 | — | $-1.6M | ||
| Q3 22 | $-14.9M | — |
| Q2 25 | — | — | ||
| Q4 24 | — | -25.5% | ||
| Q2 24 | — | — | ||
| Q3 23 | — | 12.7% | ||
| Q3 22 | — | — |
| Q2 25 | -1484.5% | — | ||
| Q4 24 | — | -77.9% | ||
| Q2 24 | -3051.1% | — | ||
| Q3 23 | — | -130.3% | ||
| Q3 22 | -342.2% | — |
| Q2 25 | -1622.4% | — | ||
| Q4 24 | — | -91.8% | ||
| Q2 24 | -3313.0% | — | ||
| Q3 23 | — | -91.4% | ||
| Q3 22 | -343.6% | — |
| Q2 25 | — | — | ||
| Q4 24 | — | $-0.06 | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $-0.04 | ||
| Q3 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $28.3M | $1.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $82.2M | $2.8M |
| Total Assets | $209.2M | $31.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $28.3M | — | ||
| Q4 24 | — | $1.9M | ||
| Q2 24 | $56.7M | — | ||
| Q3 23 | — | $853.6K | ||
| Q3 22 | $49.0M | — |
| Q2 25 | $82.2M | — | ||
| Q4 24 | — | $2.8M | ||
| Q2 24 | $135.8M | — | ||
| Q3 23 | — | $8.9M | ||
| Q3 22 | $209.1M | — |
| Q2 25 | $209.2M | — | ||
| Q4 24 | — | $31.4M | ||
| Q2 24 | $261.3M | — | ||
| Q3 23 | — | $22.5M | ||
| Q3 22 | $226.1M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
